U.S. cuts interval for Moderna COVID-19 boosters
Joe Raedle/Getty Images News


Update: Shortly after the FDA amended the emergency use authorization (EUA) issued for Moderna (NASDAQ:MRNA), shortening the interval between its primary vaccine series and the booster shot to five months, the Centers for Disease Control and Prevention (CDC) backed the move.

Previously: The U.S. Food and Drug Administration (FDA) has shortened the gap between the initial dosing regimen and the booster shot for those aged 18 years and older who received the Moderna (MRNA) COVID-19 vaccine.
According to the amended emergency use authorization (EUA) issued for the vaccine on Friday, a third dose is indicated after five months from the initial vaccine regimen. Previously, the federal agency authorized a booster shot six months after the second dose. 
Early this week, the FDA shortened the time interval for booster shots of Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine to five months from six months. However, the gap for Moderna (MRNA) COVID-19 boosters were kept unchanged.
The changes to authorization come as the U.S. is grappling with a surge in COVID-19 cases. On Monday, the country recorded over 1M cases, more than twice the single-day count of infections recorded anywhere else since the onset of the pandemic.